MiR-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting BTG2

International Journal of Molecular Sciences

Volumn 16, Issue 7, 2015, Pages 14511-14525

  Tong, Zhongyi ^a,b   Jiang, Bimei ^b   Wu, Yanyang ^c   Liu, Yanjuan ^b   Li, Yuanbin ^b   Gao, Min ^b   Jiang, Yu ^b   Lv, Qinglan ^b   Xiao, Xianzhong ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

^c HUNAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

B cell translocation gene 2 (BTG 2); Cardiotoxicity; Doxorubicin (DOX); MicroRNA 21 (miR 21)

Indexed keywords

DOXORUBICIN; LACTATE DEHYDROGENASE; MICRORNA 21; ANTINEOPLASTIC AGENT; BTG2 PROTEIN, RAT; IMMEDIATE EARLY PROTEIN; MICRORNA; MIRN21 MICRORNA, RAT; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; FLOW CYTOMETRY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CARDIAC MUSCLE CELL; CELL CULTURE; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; RAT;

MUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELLS, CULTURED; DOXORUBICIN; IMMEDIATE-EARLY PROTEINS; MICE; MICRORNAS; MYOCYTES, CARDIAC; RATS; TUMOR SUPPRESSOR PROTEINS;

EID: 84933556434     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160714511     Document Type: Article

References (32)

1. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229
2. Lefrak, E.A.; Pitha, J.; Rosenheim, S.; Gottlieb, J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32, 302–314
3. Buja, L.M.; Ferrans, V.J.; Mayer, R.J.; Roberts, W.C.; Henderson, E.S. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 1973, 32, 771–788
4. Roca-Alonso, L.; Pellegrino, L.; Castellano, L.; Stebbing, J. Breast cancer treatment and adverse cardiac events: What are the molecular mechanisms? Cardiology 2012, 122, 253–259
5. Nakamura, T.; Ueda, Y.; Juan, Y.; Katsuda, S.; Takahashi, H.; Koh, E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 2000, 102, 572–578
6. Zhang, Y.W.; Shi, J.; Li, Y.J.; Wei, L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp. 2009, 57, 435–445
7. Zhao, L.; Chen, X.; Cao, Y. New role of microRNA: Carcinogenesis and clinical application in cancer. Acta Biochim. Biophys. Sin. 2011, 43, 831–839
8. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350–355
9. Thum, T.; Catalucci, D.; Bauersachs, J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc. Res. 2008, 79, 562–570
10. Jazbutyte, V.; Thum, T. MicroRNA-21: From cancer to cardiovascular disease. Curr. Drug Targets 2010, 11, 926–935
11. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; et al. MicroRNA-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts. Nature 2008, 456, 980–984
12. Roy, S.; Khanna, S.; Hussain, S.R.; Biswas, S.; Azad, A.; Rink, C.; Gnyawali, S.; Shilo, S.; Nuovo, G.J.; Sen, C.K. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82, 21–29
13. Dong, S.; Cheng, Y.; Yang, J.; Li, J.; Liu, X.; Wang, X.; Wang, D.; Krall, T.J.; Delphin, E.S.; Zhang, C. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J. Biol. Chem. 2009, 284, 29514–29525
14. Yang, Q.; Yang, K.; Li, A. MicroRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/ akt-dependent mechanism. Mol. Med. Rep. 2014, 9, 2213–2220
15. Mao, B.; Zhang, Z.; Wang, G. BTG2: A rising star of tumor suppressors (review). Int. J. Oncol. 2015, 46, 459–464
16. Feng, Z.; Tang, Z.L.; Li, K.; Liu, B.; Yu, M.; Zhao, S.H. Molecular characterization of the BTG2 and BTG3 genes in fetal muscle development of pigs. Gene 2007, 403, 170–177
17. Choi, Y.W.; Park, T.J.; Kim, H.S.; Lim, I.K. Signals regulating necrosis of cardiomyoblast by BTG2/TIS21/PC3 via activation of GSK3β and opening of mitochondrial permeability transition pore in response to H2O2. Biochem. Biophys. Res. Commun. 2013, 434, 559–565
18. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D.D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, G.; Gabizon, A. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000, 11, 1029–1033
19. Fan, G.C.; Zhou, X.; Wang, X.; Song, G.; Qian, J.; Nicolaou, P.; Chen, G.; Ren, X.; Kranias, E.G. Heat shock protein 20 interacting with phosphorylated akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ. Res. 2008, 103, 1270–1279
20. Yang, J.; Maity, B.; Huang, J.; Gao, Z.; Stewart, A.; Weiss, R.M.; Anderson, M.E.; Fisher, R.A. G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. Cancer Res. 2013, 73, 1662–1667
21. Krishnamurthy, K.; Kanagasabai, R.; Druhan, L.J.; Ilangovan, G. Heat shock protein 25-enriched plasma transfusion preconditions the heart against doxorubicin-induced dilated cardiomyopathy in mice. J. Pharmacol. Exp. Ther. 2012, 341, 829–839
22. Huang, Y.; Yang, Y.B.; Zhang, X.H.; Yu, X.L.; Wang, Z.B.; Cheng, X.C. MicroRNA-21 gene and cancer. Med. Oncol. 2013, 30, 376
23. Zhang, S.; Han, L.; Wei, J.; Shi, Z.; Pu, P.; Zhang, J.; Yuan, X.; Kang, C. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes. Int. J. Oncol. 2015, 46, 1589–1600
24. Xu, X.; Kriegel, A.J.; Jiao, X.; Liu, H.; Bai, X.; Olson, J.; Liang, M.; Ding, X. Mir-21 in ischemia/reperfusion injury: A double-edged sword? Physiol. Genomics 2014, 46, 789–797
25. Dong, S.; Ma, W.; Hao, B.; Hu, F.; Yan, L.; Yan, X.; Wang, Y.; Chen, Z.; Wang, Z. MicroRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating BCL-2. Int. J. Clin. Exp. Pathol. 2014, 7, 565–574
26. Tirone, F. The gene PC3 (TIS21/BTG2), prototype member of the PC3/BTG/TOB family: Regulator in control of cell growth, differentiation, and DNA repair? J. Cell. Physiol. 2001, 187, 155–165
27. Zhang, Y.J.; Wei, L.; Liu, M.; Li, J.; Zheng, Y.Q.; Gao, Y.; Li, X.R. BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2013, 34, 1605–1613
28. Wei, S.; Hao, C.; Li, X.; Zhao, H.; Chen, J.; Zhou, Q. Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells. Tumour Biol. 2012, 33, 1223–1230
29. Liu, M.; Wu, H.; Liu, T.; Li, Y.; Wang, F.; Wan, H.; Li, X.; Tang, H. Regulation of the cell cycle gene, BTG2, by MIR-21 in human laryngeal carcinoma. Cell Res. 2009, 19, 828–837
30. Jiang, B.; Zhang, B.; Liang, P.; Chen, G.; Zhou, B.; Lv, C.; Tu, Z.; Xiao, X. Nucleolin protects the heart from ischaemia-reperfusion injury by up-regulating heat shock protein 32. Cardiovas. Res. 2013, 99, 92–101
31. Monte, E.; Mouillesseaux, K.; Chen, H.; Kimball, T.; Ren, S.; Wang, Y.; Chen, J.N.; Vondriska, T.M.; Franklin, S. Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1624–H1638
32. Zhang, C.; Feng, Y.; Qu, S.; Wei, X.; Zhu, H.; Luo, Q.; Liu, M.; Chen, G.; Xiao, X. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovas. Res. 2011, 90, 538–545.